Antimicrobial Peptide Elicitors (APEs) and Inhibitors (APIs): Challenges and Opportunities in Personalized Medicine

Ernesto Prado Montes de Oca
Additional contact information
Ernesto Prado Montes de Oca: Personalized Medicine National Laboratory (LAMPER), Pharmaceutical and Medical Biotechnology (BMF), Central Unit, Research Center in Technology and Design Assistance of Jalisco State (CIATEJ, A.C.), National Council of Science and Technology (CONACYT), Guadalajara, Jalisco, Mexico

Novel Approaches in Drug Designing & Development, 2017, vol. 2, issue 2, 40-42

Abstract: Antimicrobial Peptide Elicitors (APEs) and inhibitors (APIs) are physical (class I), chemical (class II) or biological agents (class III) that either up- or downregulate human antimicrobial peptide expression respectively. The up- or downregulation of antimicrobial peptides (APs) is related to the origin and/or severity of several diseases, including tuberculosis, HIV/AIDS, cancer and psoriasis among others which lead to opportunities for drug design. The development of these first in class molecules in the so-called host-directed therapy, together with companion diagnosticsoffer unique opportunities to increase efficacy and minimizing toxicity in future clinical settings. In this context, APIs and APEs could help in current treatment schemes with reduced risk of side effectsor in new schemes as e.g. MDR-TB clinical trials. The efficacy and safety of APEs and APIs remain to be demonstrated in the clinic, but this new class of molecules holds great opportunities to personalized medicine.

Keywords: juniper publishers; drug designing pdf; drug designing articles; drug designing abstract; drug designing journal; modern approaches in drug designing journal; drug designing & intellectual properties international journal; peer reviewed open access journals; high impact journals; juniper publishers review (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/napdd/pdf/NAPDD.MS.ID.555585.pdf (application/pdf)
https://juniperpublishers.com/napdd/NAPDD.MS.ID.555585.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jnapdd:v:2:y:2017:i:2:p:40-42

DOI: 10.19080/NAPDD.2017.02.555585

Access Statistics for this article

Novel Approaches in Drug Designing & Development is currently edited by Sophia Mathis

More articles in Novel Approaches in Drug Designing & Development from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().